# Bioequivalence Study of Fosinopril Sodium / Hydrochlorothiazide 20/ 12.5 mg Tablets Under Fed Conditions

> **NCT00778713** · NA · COMPLETED · sponsor: **Ranbaxy Laboratories Limited** · enrollment: 33 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Fosinopril sodium and hydrochlorothiazide 20-12.5 mg tablets

## Key facts

- **NCT ID:** NCT00778713
- **Lead sponsor:** Ranbaxy Laboratories Limited
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-03
- **Primary completion:** 2003-03
- **Final completion:** 2003-04
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2008-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00778713

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00778713, "Bioequivalence Study of Fosinopril Sodium / Hydrochlorothiazide 20/ 12.5 mg Tablets Under Fed Conditions". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00778713. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*